La Pitié-Salpêtrière
Paris, 75013, France
NCT Number: NCT07653204
PAnDA-One is a prospective, multicenter, interventional study (10 centers, France) aimed at developing and validating a diagnostic support algorithm based on the ADx-One medical device, which non-invasively acquires thoracic vibrations using airborne ultrasound.
The study will enroll 2,500 patients presenting to the emergency department with acute dyspnea or non-traumatic chest pain, divided into a development cohort (N = 1,500) and an independent test cohort (N = 1,000). The deep learning algorithm will be trained to discriminate cardiovascular from non-cardiovascular origins of symptoms, and its performance will be assessed by AUROC, sensitivity, and specificity against a final diagnosis established by an expert adjudication committee.
Patient management will not be modified by study participation.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Paris, 75013, France
Acute dyspnea is a common reason for emergency department (ED) presentation, accounting for 7 to 12% of all consultations (Mockel et al., 2013). More than half of these patients are over 65 years of age - a population whose respiratory system is particularly vulnerable due to parenchymal degeneration and age-related decline in ventilatory and immune function (Boisguérin et Mauro, 2017). In the ED, the leading causes of acute dyspnea are acute heart failure, respiratory tract infections, exacerbations of asthma or chronic obstructive pulmonary disease, and pulmonary embolism (Ray et al., 2006). These episodes frequently lead to hospitalization and carry substantial mortality - reaching 10% in acute heart failure, for instance (Freund et al., 2020) - as well as a marked loss of autonomy, whether driven by the respiratory impairment itself or by the deconditioning that follows prolonged hospital stays.
Non-traumatic chest pain is another major reason for ED presentation, accounting for 5-10% of all visits, and shares with dyspnea the requirement for rapid etiological triage between life-threatening cardiovascular causes - acute coronary syndrome, pulmonary embolism, acute aortic syndrome, pericarditis, pneumothorax - and benign musculoskeletal or functional causes. Despite the ECG, high-sensitivity troponin and validated clinical scores, missed acute coronary syndrome at ED discharge has been reported in approximately 2% of patients (Pope et al., 2000), and the widespread use of "rule-out" strategies drives substantial use of coronary CTA and CT pulmonary angiography, with associated radiation exposure, costs and observation admissions. Diagnostic uncertainty is particularly pronounced in younger adults and in women, in whom the pretest probability of acute coronary syndrome is lower but pulmonary embolism, pneumothorax and pericarditis carry a non-negligible relative weight. Furthermore, several studies continue to highlight the increased use of irradiative imaging studies, with no clinical benefit in terms of diagnostic and prognostic (Roussel et al., 2023).
At present, the etiological work-up of acute dyspnea and chest pain relies on the combination of clinical examination, laboratory testing, and chest radiography (Olson et Davis, 2020; Miró et al., 2025). This strategy has well-documented limitations in the ED, particularly in older patients:
ADx-One is an airborne ultrasound device which relies on Surface Motion Camera technology.
The ADx-One device is based on the non-invasive acquisition of minute chest surface movements induced by cardiopulmonary activity (~100 µm), using airborne ultrasound. These vibrations, resulting from mechanical interactions between the heart, lungs, and chest wall, constitute a physical signature that integrates multiple pathophysiological determinants (Shirkovskiy et al., 2018).
In particular, any modification in intrathoracic composition or mechanical properties-whether due to the presence of fluid (congestion, effusion), solid tissue changes (consolidation, atelectasis), or abnormal air presence (pneumothorax)-is likely to alter these vibratory signatures.
The overall purpose of this clinical investigation is to collect ADx-One acquisition data in emergency department patients in order to develop and evaluate on distinct cohorts a diagnostic support algorithm intended to assist discrimination of the origin of acute cardiopulmonary symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients from both cohorts will follow their usual routine, except for stepping in front of the machine so that one or two images of their chest and back can be taken.
Time frame: Within the first hour after ED admission.
Diagnostic performance for distinguishing cardiovascular from non-cardiovascular involvement, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of acute heart failure with pulmonary edema, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of chronic obstructive pulmonary disease, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of lower respiratory tract infection, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of absence of both pulmonary and cardiovascular involvement, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for distinguishing pulmonary from non-pulmonary involvement, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC. Pulmonary involvement is defined as any diagnosis of pulmonary or parenchymal lesion or bronchial involvement, including (but not limited to): upper respiratory tract infection, lower respiratory tract infection, exacerbation of obstructive ventilatory disorder such as asthma or COPD.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of interstitial syndrome, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of a left ventricular ejection fraction < 55% at cardiac echography at any point in the month before or after the inclusion, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of pulmonary embolism, diagnosed either at computed tomography pulmonary angiogram or V/Q scan, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of upper respiratory tract infection, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of atelectasis, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of alveolar syndrome, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of pleural effusion, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC.
Time frame: Within the first hour after ED admission.
Diagnostic performance for the diagnosis of pneumothorax, including sensitivity, specificity, positive and negative predictive values, likelihood ratios, and AUROC
Contact information is provided by the study sponsor or research team.
Austral Diagnostics
Industry
Prospective Study for Data Acquisition in Emergency Departments to Develop a Discrimination Algorithm for the Origin of Dyspnea and Chest Pain Using the ADx-One Medical Device
Acronym: PAnDA-One
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07727590
Acute Cardiopulmonary Disease, Chest Pain
Seoul, South Korea
View Trial DetailsNCT05907018
Chest Pain, Consciousness Disorders
Cincinnati, Ohio, United States
View Trial DetailsNCT01345188
Cardiomyopathies, Cardiomyopathy
Davenport, Iowa, United States
View Trial DetailsNCT05329246
Breath Shortness, Cardiovascular Diseases
Bardejov, Slovakia
View Trial Details